Daisy Michelle Princeton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daisy Michelle Princeton has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Christina Narelle Parker
School of Nursing Queensland University of Technology Brisbane Queensland Australia
1 shared publication - Gülendam Hakverdioğlu Yönt
Izmir Tinaztepe University
1 shared publication - Jane O'BRien
School of Nursing, Centre for Healthcare Transformation, Faculty of Health Queensland University of Technology Brisbane Queensland Australia
1 shared publication Linda Iren Mihaila Hansen
Department of Health and Nursing Science University of Agder Kristiansand Norway
1 shared publicationRosie Glynn
Kelvin Grove Library Queensland University of Technology Brisbane Australia
1 shared publicationSezer Kisa
Department of Nursing and Health Promotion, Faculty of Health Sciences Oslo Metropolitan University Oslo Norway
1 shared publication
Latest Publications
- Open Access
- 11 January 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (1) , e70830
The Effectiveness, Safety and Cost‐Effectiveness of Platelet‐Rich Plasma and Platelet‐Rich Fibrin in the Treatment of Venous Leg Ulcers: A Systematic Review and Meta‐Analysis
Venous leg ulcers occur due to chronic venous insufficiency in the lower extremities and are often difficult to heal. Platelet‐rich plasma and platelet‐rich fibrin are products that contain high concentrations of platelets. This systematic review evaluated the effectiveness, safety and cost‐effectiveness of these products for the treatment of venous leg ulcers. Guided by the 2020 Joanna Briggs Institute systematic review of effectiveness guideline, this review included original studies that investigated platelet‐rich plasma and platelet‐rich fibrin in the treatment of venous leg ulcers from databases including the Cochrane Library, Embase, Medline, CINAHL, PubMed, World Health Organisation International Clinical Trials Registry, Clinical Trials.gov and Australian New Zealand Clinical Trials Registry. Methodological quality was assessed using relevant appraisal checklists. Information related to general characteristics of included articles and relevant outcomes of interest were extracted and synthesised narratively. Of thirty‐six eligible studies, 24 studies used platelet‐rich plasma, eleven investigated fibrin‐rich plasma and one study used both platelet‐rich plasma and fibrin‐rich. Most studies reported these products were effective in promoting wound healing, reducing other symptoms, and were safe to use. The use of platelet‐rich plasma and platelet‐rich fibrin resulted in significantly higher healed venous leg ulcers compared to control using conventional treatment (RR: 2.93, 95% CI, 1.90–4.53, p = 0.01). These products were safe to used topically and promoted to wound healing, reduced pain, either along or combined with other treatments. Platelet‐rich plasma and fibrin‐rich plasma improves wound healing and appears to be safe to use in the treatment of venous leg ulcers.
- 11 January 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (1) , e70830
Open AccessThe Effectiveness, Safety and Cost‐Effectiveness of Platelet‐Rich Plasma and Platelet‐Rich Fibrin in the Treatment of Venous Leg Ulcers: A Systematic Review and Meta‐Analysis
Venous leg ulcers occur due to chronic venous insufficiency in the lower extremities and are often difficult to heal. Platelet‐rich plasma and platelet‐rich fibrin are products that contain high concentrations of platelets. This systematic review evaluated the effectiveness, safety and cost‐effectiveness of these products for the treatment of venous leg ulcers. Guided by the 2020 Joanna Briggs Institute systematic review of effectiveness guideline, this review included original studies that investigated platelet‐rich plasma and platelet‐rich fibrin in the treatment of venous leg ulcers from databases including the Cochrane Library, Embase, Medline, CINAHL, PubMed, World Health Organisation International Clinical Trials Registry, Clinical Trials.gov and Australian New Zealand Clinical Trials Registry. Methodological quality was assessed using relevant appraisal checklists. Information related to general characteristics of included articles and relevant outcomes of interest were extracted and synthesised narratively. Of thirty‐six eligible studies, 24 studies used platelet‐rich plasma, eleven investigated fibrin‐rich plasma and one study used both platelet‐rich plasma and fibrin‐rich. Most studies reported these products were effective in promoting wound healing, reducing other symptoms, and were safe to use. The use of platelet‐rich plasma and platelet‐rich fibrin resulted in significantly higher healed venous leg ulcers compared to control using conventional treatment (RR: 2.93, 95% CI, 1.90–4.53, p = 0.01). These products were safe to used topically and promoted to wound healing, reduced pain, either along or combined with other treatments. Platelet‐rich plasma and fibrin‐rich plasma improves wound healing and appears to be safe to use in the treatment of venous leg ulcers.
- Open Access
- 8 December 2025
- Published by IntechOpen
Ethical Considerations and Informed Consent in the Use of Physical Restraints in Healthcare
The use of physical restraints in healthcare is a complex and ethically sensitive practice that requires carefully balancing patient safety with respect for autonomy, dignity, and fundamental human rights. While restraints can sometimes be necessary to prevent immediate harm, their use carries substantial risks, including physical injury, psychological distress, diminished freedom, loss of personal autonomy, social isolation, a sense of abandonment, and erosion of trust in the therapeutic relationship. This chapter critically examines the ethical principles underpinning decisions about physical restraint, including beneficence, non-maleficence, autonomy, and justice, and highlights the tensions that arise when these principles conflict. It emphasizes individualized clinical assessments, challenges around informed consent, the role of multidisciplinary decision-making, and practical strategies for resolving ethical dilemmas. Furthermore, it underscores the need for strict adherence to legal and institutional policies to safeguard patient rights and ensure accountability. By adopting a reflective and rights-based approach, healthcare professionals can minimize restraint use, uphold ethical standards, and foster a culture of care that prioritizes dignity, compassion, and patient-centered practice.
- 8 December 2025
- Published by IntechOpen
Open AccessEthical Considerations and Informed Consent in the Use of Physical Restraints in Healthcare
The use of physical restraints in healthcare is a complex and ethically sensitive practice that requires carefully balancing patient safety with respect for autonomy, dignity, and fundamental human rights. While restraints can sometimes be necessary to prevent immediate harm, their use carries substantial risks, including physical injury, psychological distress, diminished freedom, loss of personal autonomy, social isolation, a sense of abandonment, and erosion of trust in the therapeutic relationship. This chapter critically examines the ethical principles underpinning decisions about physical restraint, including beneficence, non-maleficence, autonomy, and justice, and highlights the tensions that arise when these principles conflict. It emphasizes individualized clinical assessments, challenges around informed consent, the role of multidisciplinary decision-making, and practical strategies for resolving ethical dilemmas. Furthermore, it underscores the need for strict adherence to legal and institutional policies to safeguard patient rights and ensure accountability. By adopting a reflective and rights-based approach, healthcare professionals can minimize restraint use, uphold ethical standards, and foster a culture of care that prioritizes dignity, compassion, and patient-centered practice.